At Last: Acadia Submits NDA, Makes Davis Permanent CEO
This article was originally published in Scrip
Following delay after delay, Acadia Pharmaceuticals finally submitted a new drug application (NDA) to the US FDA seeking approval for Nuplazid (pimavanserin) nearly three years after the company reported positive Phase III results in the treatment of Parkinson's disease psychosis (PDP).
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
Amunix’s XTEN technology for half-life extension and precise drug delivery has been used by multiple partners over the past 15 years, but now the firm is building its own cancer therapy pipeline.
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.